Note 15 - Segment Information

12 Months Ended

Dec. 31, 2025

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

15. Segment Information

Segment reporting is prepared on the same basis that our chief executive officer, who is our CODM, manages the business, makes operating decisions and assesses performance. The Company operates in one segment. The Company’s business is research and development of drug candidates. Costs, including supplies, outsourced development, and other research and development costs are tracked by major program. While internal personnel costs are tracked by program for overall program spending, it is not broken out for management review. Facility and equipment costs are not allocated to programs. Research and development expenses are summarized by program in the table below:

	Year Ended December 31,
	2025			2024
	(000's)
Licensing revenue	$	—		$	850
Personnel		11,935			9,918
General		4,616			3,965
Tovecimig		23,680			23,177
CTX-471		4,183			2,879
CTX-8371		3,355			2,403
CTX-10726		8,200			—
Research and development		55,969			42,342
Personnel		10,236			10,472
General		6,634			4,661
General and administrative		16,870			15,133
Other income		6,350			7,250
Net loss	$	(66,489	)	$	(49,375	)